Quintrigen
Targeted Anti-cancer and Tumor Suppressor Drug
Company Overview
Snapshot
Founded in May 2019 by Orna Palgi and Anat Nursella, Quintrigen operates with 1–10 employees. The company's primary focus is on developing a p53 anti-cancer drug, a technology that emerged from the Weizmann Institute.
Business overview
Quintrigen is a Health Tech & Life Sciences company focused on the development of targeted anti-cancer and tumor suppressor drugs. The company's core technology involves identifying small peptides that can reactivate mutant p53 proteins, refolding them to restore their natural function and induce cancer cell death. This treatment is designed to be highly selective against cancer cells while sparing normal tissues. Quintrigen operates within the Pharmaceuticals & Diagnostics sector, specifically in Drugs Discovery & Development, targeting the Life Sciences and Pharmaceutical industries.
Strategic signal
In October 2019, Quintrigen was established as a joint venture between South Korea's Bioleaders and Israel's Weizmann Institute to advance p53-targeted research and development. This collaboration signals a strategic partnership leveraging academic research with biotech expertise to accelerate the development of a novel anti-cancer drug, indicating a strong foundational backing for its early-stage R&D.
Company Intelligence Q&A
- What is Quintrigen's primary therapeutic focus?
- Quintrigen is developing p53, a targeted anti-cancer and tumor suppressor drug, which utilizes small peptides to reactivate mutant p53 proteins and induce cancer cell death.
- When was Quintrigen founded?
- Quintrigen was founded in May 2019.
- Who are the founders of Quintrigen?
- Quintrigen was founded by Orna Palgi and Anat Nursella.
- What is the nature of Quintrigen's foundational partnership?
- In October 2019, Quintrigen was formed as a joint venture between South Korea's Bioleaders and Israel's Weizmann Institute to advance p53-targeted research and development.
- What is the current status of Quintrigen?
- Quintrigen is currently non-active, having ceased operations in July 2025.